De-escalating treatment after HER2-positive breast cancer responds
Treatments studied
Part of Cancer, Skin clinical trials.
This study looks at whether some people with HER2-positive breast cancer can safely receive less (de-escalated) treatment after they finish chemotherapy plus HER2-targeted drugs before surgery. It specifically focuses on people whose cancer shows a complete response on the surgery pathology report.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HER2-positive breast cancer (hormone receptor status can be positive or negative)
- Your cancer stage is I, II, or III
- You planned and received neoadjuvant therapy (before surgery) with chemotherapy plus trastuzumab and pertuzumab
- You had breast surgery after finishing the pre-surgery treatment
- Your recovery status is ECOG 0 to 3 (you can still do some daily activities)
- For the randomization part: your surgery test shows ypT0 or ypTis and ypN0 (no remaining tumor in the breast and no lymph node spread)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether Herceptin (trastuzumab) can be used as after-treatment with less chemotherapy for certain early breast cancers. It may help reduce how much chemotherapy you need, while still lowering the chance the cancer comes back.
This trial tests a new drug called trastuzumab rezetecan given before surgery for early-stage HER2-positive breast cancer. It's designed for patients whose cancer doesn't respond well to standard HER2-targeted treatments.
This Phase 2 study tests two different medicines given after breast surgery to reduce the risk of cancer coming back. It is only for people with early-stage HER2-positive breast cancer with limited or no lymph node spread.
This trial looks at the best next treatment for women with HER2-positive breast cancer who still have leftover cancer after surgery and standard pre-surgery treatment. It helps doctors choose the right therapy for you.
This Phase 2 study tests whether treatment can be reduced (de-escalated) for people with early-stage (stage I) HER2-positive invasive breast cancer. It aims to keep the cancer under control while potentially reducing treatment intensity and side effects.
This trial tests a personalized approach to chemotherapy before surgery for HER2-positive breast cancer. The treatment is adjusted based on how your tumor responds, aiming to give the right amount of therapy for better outcomes.
Hear when a new Breast Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.